{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2023"],"data_sharing_plan":["IPD Sharing (as of May 2023): No"],"condition":["Pancreatic Cancer Metastatic","Colon Cancer","Colorectal Cancer Metastatic","Colorectal Neoplasms","Pancreatic Neoplasms","Neoplasms"],"disease":["Pancreatic Cancer Metastatic","Colon Cancer","Colorectal Cancer Metastatic","Colorectal Neoplasms","Pancreatic Neoplasms","Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2370817"],"study_start_month":["5"],"keyword":["Retifanlimab","Poly ICLC","Anti-PD-1","Pancreatic Ductal Adenocarcinoma (PDAC)","Immunotherapy","Cancer Vaccines","Neoantigen Vaccines","Carboxymethylcellulose Sodium","Metastatic colon cancer","Poly I-C","Metastatic pancreatic cancer"],"repository":["ECRIN MDR"],"study_status":["Withdrawn"],"additional_accession":[]},"is_claimable":false,"name":"Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer","description":"Phase 1 study evaluating feasibility, safety, and immune response to a personalized neoantigen vaccine combined with retifanlimab for MMR-p mCRC and mPDAC patients with measurable disease following first-line FOLFIRINOX/FOLFOXIRI (FFX).","dates":{"creation":"2023-05-15"},"accession":"2370817","cross_references":{"ClinicalTrials___gov":["NCT04799431"]}}